These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 16299871)

  • 1. Growth hormone treatment in 35 prepubertal children with achondroplasia: a five-year dose-response trial.
    Hertel NT; Eklöf O; Ivarsson S; Aronson S; Westphal O; Sipilä I; Kaitila I; Bland J; Veimo D; Müller J; Mohnike K; Neumeyer L; Ritzen M; Hagenäs L
    Acta Paediatr; 2005 Oct; 94(10):1402-10. PubMed ID: 16299871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skeletal dysplasia, growth hormone treatment and body proportion: comparison with other syndromic and non-syndromic short children.
    Hagenäs L; Hertel T
    Horm Res; 2003; 60 Suppl 3():65-70. PubMed ID: 14671400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth hormone treatment of short children born small-for-gestational-age: the Nordic Multicentre Trial.
    Boguszewski M; Albertsson-Wikland K; Aronsson S; Gustafsson J; Hagenäs L; Westgren U; Westphal O; Lipsanen-Nyman M; Sipilä I; Gellert P; Müller J; Madsen B
    Acta Paediatr; 1998 Mar; 87(3):257-63. PubMed ID: 9560030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Favorable Growth Hormone Treatment Response in a Young Boy with Achondroplasia.
    Krstevska-Konstantinova M; Stamatova A; Gucev Z
    Med Arch; 2016 Apr; 70(2):148-50. PubMed ID: 27147792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three-year growth hormone treatment in short children with X-linked hypophosphatemic rickets: effects on linear growth and body disproportion.
    Živičnjak M; Schnabel D; Staude H; Even G; Marx M; Beetz R; Holder M; Billing H; Fischer DC; Rabl W; Schumacher M; Hiort O; Haffner D;
    J Clin Endocrinol Metab; 2011 Dec; 96(12):E2097-105. PubMed ID: 21994957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth and growth hormone therapy in children with achondroplasia: a two-year experience.
    Stamoyannou L; Karachaliou F; Neou P; Papataxiarchou K; Pistevos G; Bartsocas CS
    Am J Med Genet; 1997 Oct; 72(1):71-6. PubMed ID: 9295079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Final height data, body composition and glucose metabolism in growth hormone-treated short children born small for gestational age.
    Hokken-Koelega AC; van Pareren Y; Sas T; Arends N
    Horm Res; 2003; 60 Suppl 3():113-4. PubMed ID: 14671407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of growth hormone therapy in children with achondroplasia: growth pattern, hypothalamic-pituitary function, and genotype.
    Tanaka H; Kubo T; Yamate T; Ono T; Kanzaki S; Seino Y
    Eur J Endocrinol; 1998 Mar; 138(3):275-80. PubMed ID: 9539301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of achondroplasia with growth hormone: six years of experience.
    Ramaswami U; Rumsby G; Spoudeas HA; Hindmarsh PC; Brook CG
    Pediatr Res; 1999 Oct; 46(4):435-9. PubMed ID: 10509364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-year data from a comparative study with recombinant human growth hormone in the treatment of short stature in young children with intrauterine growth retardation.
    Fjellestad-Paulsen A; Czernichow P; Brauner R; Bost M; Colle M; Lebouc JY; Lecornu M; Leheup B; Limal JM; Raux MC; Toublanc JE; Rappaport R
    Acta Paediatr; 1998 May; 87(5):511-7. PubMed ID: 9641731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of different definitions of growth response in short prepubertal children treated with growth hormone.
    Bang P; Bjerknes R; Dahlgren J; Dunkel L; Gustafsson J; Juul A; Kriström B; Tapanainen P; Aberg V
    Horm Res Paediatr; 2011; 75(5):335-45. PubMed ID: 21228552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 levels during growth hormone treatment in prepubertal short children born small for gestational age.
    Boguszewski M; Jansson C; Rosberg S; Albertsson-Wikland K
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3902-8. PubMed ID: 8923836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attaining genetic height potential: Analysis of height outcomes from the ANSWER Program in children treated with growth hormone over 5 years.
    Ross JL; Lee PA; Gut R; Germak J
    Growth Horm IGF Res; 2015 Dec; 25(6):286-93. PubMed ID: 26363846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early, discontinuous, high dose growth hormone treatment to normalize height and weight of short children born small for gestational age: results over 6 years.
    de Zegher F; Du Caju MV; Heinrichs C; Maes M; De Schepper J; Craen M; Vanweser K; Malvaux P; Rosenfeld RG
    J Clin Endocrinol Metab; 1999 May; 84(5):1558-61. PubMed ID: 10323379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth hormone (GH) dose-dependent IGF-I response relates to pubertal height gain.
    Lundberg E; Kriström B; Jonsson B; Albertsson-Wikland K;
    BMC Endocr Disord; 2015 Dec; 15():84. PubMed ID: 26682747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of growth hormone therapy on height in children with idiopathic short stature: a meta-analysis.
    Finkelstein BS; Imperiale TF; Speroff T; Marrero U; Radcliffe DJ; Cuttler L
    Arch Pediatr Adolesc Med; 2002 Mar; 156(3):230-40. PubMed ID: 11876666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Age at growth hormone therapy start and first-year responsiveness to growth hormone are major determinants of height outcome in idiopathic short stature.
    Ranke MB; Lindberg A; Price DA; Darendeliler F; Albertsson-Wikland K; Wilton P; Reiter EO;
    Horm Res; 2007; 68(2):53-62. PubMed ID: 17228181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth hormone therapy in pre-pubertal children with Noonan syndrome: first year growth response and comparison with Turner syndrome.
    De Schepper J; Otten BJ; François I; Bourguignon JP; Craen M; Van der Burgt I; Massa GG
    Acta Paediatr; 1997 Sep; 86(9):943-6. PubMed ID: 9343272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Height velocity targets from the national cooperative growth study for first-year growth hormone responses in short children.
    Bakker B; Frane J; Anhalt H; Lippe B; Rosenfeld RG
    J Clin Endocrinol Metab; 2008 Feb; 93(2):352-7. PubMed ID: 18000092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The growth and cardiovascular effects of high dose growth hormone therapy in idiopathic short stature.
    Barton JS; Gardineri HM; Cullen S; Hindmarsh PC; Brook CG; Preece MA
    Clin Endocrinol (Oxf); 1995 Jun; 42(6):619-26. PubMed ID: 7634503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.